Well it seems that the enthusiasm has been squashed out of the retail shareholders.. A most intriguing pair of announcements.
It would seem that the appointment of a new Lyramid CEO preempts an almost certain spin off. I wouldn't think that Bart would have accepted this opportunity if there wasn't a fair chance of success...as soon as the FDA provide Orphan Drug Designation. Has anyone checked the mailbox ? probably sitting on the bottom of the in-tray and may have the ceremonial "surprise" opening in the very near term.
So what leaves the CEO of Advandgen ? Where does that leave Maria ? Perhaps as new Chair ??
And where does the leave Kinera ? all a bit of a mystery really.
The push to expose value to the shareholders can have no more importance than to that of the CEO ? Is this an exit plan ?
regardless of the plan i think there are a few more ann to come before eofy.
- Forums
- ASX - By Stock
- AN1
- Cellmid Growth Trifecta
Cellmid Growth Trifecta, page-16
Featured News
Add AN1 (ASX) to my watchlist
|
|||||
Last
0.8¢ |
Change
-0.001(11.1%) |
Mkt cap ! $3.691M |
Open | High | Low | Value | Volume |
0.8¢ | 0.9¢ | 0.8¢ | $8.671K | 1.051M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1735002 | 0.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.9¢ | 340000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 1735002 | 0.008 |
3 | 1953225 | 0.007 |
4 | 1006527 | 0.006 |
1 | 300000 | 0.005 |
2 | 525000 | 0.004 |
Price($) | Vol. | No. |
---|---|---|
0.009 | 340000 | 1 |
0.010 | 100000 | 1 |
0.011 | 100000 | 1 |
0.012 | 300000 | 2 |
0.013 | 750000 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
AN1 (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online